Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alcidion Group Limited ( (AU:ALC) ) just unveiled an update.
Alcidion Group Limited has expanded its contract with Leidos Australia to enhance the use of its Miya Precision software, securing a total contract value of $12.3 million until June 2028. This expansion is expected to add $2.5 million to Alcidion’s annual recurring revenue, with significant revenue recognition projected for FY26, aligning with a larger contract that could extend to 2036, thus strengthening Alcidion’s market position in healthcare technology.
The most recent analyst rating on (AU:ALC) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.
More about Alcidion Group Limited
Alcidion Group Limited is a healthcare technology company focused on transforming healthcare through smart, intuitive technology solutions that enhance patient care efficiency and quality. Their flagship product, Miya Precision, supports interoperability and clinical decision-making, serving over 400 hospitals and 87 healthcare organizations across the UK, Australia, and New Zealand.
Average Trading Volume: 790,533
Technical Sentiment Signal: Buy
Current Market Cap: A$131.6M
For a thorough assessment of ALC stock, go to TipRanks’ Stock Analysis page.